Title :

Safety of 2’-fucosyllactose/difucosyllactose mixture as a novel food pursuant to Regulation (EU) 2015/2283

Author(s) :

Turck, Dominique [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Castenmiller, Jacqueline [Auteur]
De Henauw, Stefaan [Auteur]
Hirsch-Ernst, Karen Ildico [Auteur]
Kearney, John [Auteur]
Maciuk, Alexandre [Auteur]
Mangelsdorf, Inge [Auteur]
Mcardle, Harry J. [Auteur]
Naska, Androniki [Auteur]
Pelaez, Carmen [Auteur]
Pentieva, Kristina [Auteur]
Siani, Alfonso [Auteur]
Thies, Frank [Auteur]
Tsabouri, Sophia [Auteur]
Vinceti, Marco [Auteur]
Cubadda, Francesco [Auteur]
Engel, Karl-Heinz [Auteur]
Frenzel, Thomas [Auteur]
Heinonen, Marina [Auteur]
Marchelli, Rosangela [Auteur]
Neuhauser-Berthold, Monika [Auteur]
Poting, Annette [Auteur]
Poulsen, Morten [Auteur]
Sanz, Yolanda [Auteur]
Schlatter, Josef Rudolf [Auteur]
van Loveren, Henk [Auteur]
Sun, Qingqing [Auteur]
Turla, Emanuela [Auteur]
Knutsen, Helle Katrine [Auteur]

Journal title :

EFSA Journal

Abbreviated title :

EFSA J.

Volume number :

17

Pages :

e05717

Publication date :

2019-06

ISSN :

1831-4732

English keyword(s) :

oligosaccharide
safety
novel food
DFL
2 '-FL
difucosyllactose
2 '-fucosyllactose

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on 2’-fucosyllactose/difucosyllactose (2’-FL/DFL) mixture as a novel food ...
Show more >Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on 2’-fucosyllactose/difucosyllactose (2’-FL/DFL) mixture as a novel food (NF) pursuant to Regulation (EU) 2015/2283. The NF is a powdered mixture mainly composed of two oligosaccharides, 2’-FL and DFL, which are produced together by fermentation with a genetically modified strain of Escherichia coli K12. The information provided on the manufacturing process, composition and specifications of the NF does not raise safety concerns. The applicant intends to add the NF in a variety of foods, including infant and follow-on formula, foods for infants and young children, foods for special medical purposes and food supplements. The target population is the general population except for food supplements, for which the target population is individuals above 1 year of age. Since the intake of 2’-FL and DFL from the NF at the proposed use levels is unlikely to exceed the intake level of naturally occurring 2’-FL and DFL in breastfed infants per kilogram body weight, the Panel concludes that the NF, a mixture of 2’-FL and DFL, is safe under the proposed conditions of use for the proposed target population.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

CHU Lille
Inserm
Université de Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Submission date :

2024-01-30T10:27:42Z
2024-02-05T10:35:32Z